Action signal — 🔍 Research

Surfaced by the 2026-10-09 actions digest.

Action: 🔍 Research (LOW) RSI: 38.2

Why this is in actions

NEW — Revolution Medicines: thesis rated intact-but-priced, well above its 200-day. Sourced: shares fell more than 6% after new data showed a lower response rate for its drug Rasonque in the most common KRAS mutation in pancreatic cancer (Endpoints, October 9)

Trade Summary

Stub — 🔍 Research means more research needed before action.

Sources

• Actions digest: 2026-10-09-actions-daily-digest
• Original row: | RVMD | $189.76 | hold the 200-day ($148.91) | 38.2 | -8.63% | 298.49% | 27.4% | 2026-10-09 | monster-scan (Secular) | 🔍 Research | NEW — Revolution Medicines: thesis rated intact-but-priced, well a
• Price truth: summaries